Susquehanna International Group, LLP Sigilon Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 16, 2023	BUY	$0.34 - $1.38 $5,610 - $22,770	16,500 New	16,500 $15,000
Q1 2022 May 16, 2022	SELL	$1.24 - $3.03 $124 - $303	-100 Reduced 0.33%	30,000 $44,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $77,658 - $184,513	30,100 New	30,100 $83,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.